A third anti-SARS-Cov2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

Haematologica. 2021 Nov 18. doi: 10.3324/haematol.2021.280026. Online ahead of print.ABSTRACTNot available.PMID:34788987 | DOI:10.3324/haematol.2021.280026

Source: Haematologica - November 18, 2021 Category: Hematology Authors: Milena Kohn Marc Delord Maureen Chbat Amina Guemriche Fatiha Merabet Anne-Laure Roupie Naelle Lombion Hassan Farhat Thomas Longval Aur élie Cabannes-Hamy Juliette Lambert St éphanie Marque-Juillet Victoria Raggueneau Jennifer Osman Marc Spentchian Sophi Source Type: research